Author: Customer Service

Collaboration combines Lufthansa Technik’s engine services expertise with Woodward’s leading technology to ensure efficiency and increase uptime for CFM LEAP engine-powered aircraft FORT COLLINS, Colo., April 22, 2026 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ: WWD) and Lufthansa Technik have entered an Elite Licensed Repair Service Facility Agreement (LRSF), reinforcing their long-standing cooperation for support of Woodward components on the CFM International LEAP-1A and LEAP-1B* engines. As part of Woodward’s newly established two-tier global support network, Lufthansa Technik is the first network partner authorized to provide the complete range of repair and overhaul services on Woodward fuel controls, valves, and actuators on the CFM LEAP engines. For operators of Airbus A320neo and Boeing 737 MAX aircraft, this agreement will...

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are expected to be $150 million. The offering is expected to close on or about April 23, 2026, subject...

SHENZHEN, China, April 21, 2026 (GLOBE NEWSWIRE) — On April 17th, Han’s Laser (002008.SZ) released its 2025 annual report. The report indicates that Han’s Laser exceeded annual revenue of USD 2.67 billion, up 27.00% year-on-year, marking a three-year high in revenue scale. Its net profit attributable to shareholders of the listed company was CNY 1.19 billion, while its net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was CNY 810 million, with the latter surging by as much as 82.28% year-on-year, reflecting continuous improvement in its operating quality. Driven by the three major trends of explosive growth in AI computing power, the globalization of new energy, and the domestic substitution of semiconductors, Han’s Laser leverages its vertically integrated technological advantages...

NATIONAL HARBOR, Md., April 21, 2026 (GLOBE NEWSWIRE) — At the U.S. Navy League’s Sea-Air-Space Exposition 2026 today, Kari Wilkinson, HII (NYSE: HII) executive vice president and president of Newport News Shipbuilding, highlighted the company’s commitment to strengthen and expand the U.S. maritime industrial base. Wilkinson served as a panelist for a discussion on advancing strategic requirements with a resilient shipbuilding enterprise. The shipbuilding panel examined the broad initiatives shaping the maritime industrial base and how policy, budgeting, and long term planning can sustain the nation’s maritime dominance. Chris Miller, the U.S. Navy’s portfolio acquisition executive for maritime (PAE Maritime), moderated the discussion. During the panel, Wilkinson highlighted how HII is growing and retaining the workforce needed...

MEXICO CITY, April 21, 2026 (GLOBE NEWSWIRE) — Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO) (“Aeroméxico”) will hold a live conference call and webcast on Wednesday, April 22, 2026, at 10:30 a.m. Mexico City Time (12:30 p.m. Eastern Time / NY Time) to discuss its first quarter 2026 financial results. During the call, management will review the company’s operating and financial performance for the period, highlighting key business drivers, recent developments, and strategic initiatives that shaped Aeroméxico’s results throughout the first quarter. The event will also include a Q&A session for investors and analysts. A live webcast of this event will be available at https://ir.aeromexico.com/ and an online replay will be available shortly after the webcast is complete.Conference Call Details Date: Wednesday,...

ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstracts selected for poster presentations, these data highlight the global innovation and clinical value of Ascentage Pharma’s portfolio, inclusive...

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) — Figure Technology Solutions (Nasdaq: FIGR; OPEN: FGRS), the leading blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, today announced that it plans to report its First Quarter 2026 results on Monday, May 11, 2026, after market close. The company will host a conference call to discuss the results, outlook, and related matters the following morning, Tuesday, May 12, 2026, at 8:30 a.m. Eastern Time. A live webcast of the conference call and supporting materials will be available at http://investors.figure.com. For those unable to listen to the live broadcast, a replay will be available at the same website after the event. About Figure Figure Technology Solutions, Inc. (Nasdaq: FIGR; OPEN: FGRS) is a blockchain-native capital marketplace...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS) Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide Fenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral for both RMS and primary progressive multiple sclerosis (PPMS) The totality of RMS and PPMS data for fenebrutinib will be submitted to regulatory authoritiesBasel, 22 April 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed that fenebrutinib, an investigational non-covalent Bruton’s tyrosine...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for patients and caregivers Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive primary analysis results from its registrational trial, KYSA-8, of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome (SPS). The data...